Triple-negative breast cancer

Triple-negative breast cancer (TNBC) is a heterogeneous group of breast cancers, characterized by a lack of expression of estrogen receptors, progesterone receptors, and amplification of the human epidermal growth factor receptor 2 gene (HER2), which make it unresponsive to hormone therapy, such as tamoxifen or aromatase inhibitors, and HER2-targeted treatment, such as Herceptin or Tykerb.

TNBC accounts for 12 to 17% of primary breast cancer. TNBC is the most aggressive breast cancer subtype, with the highest mortality. The heterogeneity of TNBC and its lack of targeted therapies represent the main considerations for patients , most patients being treated with surgery, radio- and chemo-therapy.

Research into better biomarkers to characterize TNBC metabolically and into new treatments will be key to improving outcomes in TNBC.